Neuren Pharmaceuticals Ltd has released a press release.
Neuren receives US$40m milestone payment
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Q1 2023 quarterly activity and cash flow report
- DAYBUE (trofinetide) launched in US - Neuren earns US$40m
- FDA approves Daybue - the first treatment for Rett syndrome
- Neuren reports 2022 full-year results
- Appendix 4E and 2022 full year accounts
Later from Neuren Pharmaceuticals
- Neuren opens first site in US for Prader-Willi Phase 2 trial
- Neuren completes enrolment in Phelan-McDermid Phase 2 trial
- Neuren and Acadia expand global partnership for trofinetide
- Neuren receives US$100m for expanded DAYBUE agreement
- Q2 2023 quarterly activity and cash flow report
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals